Naratriptan

證據等級: L5

預測適應症: 10 個

Naratriptan: From Migraine to Migraine with Brainstem Aura

One-Sentence Summary

Naratriptan is a selective 5-HT1B/1D receptor agonist (triptan class) originally used for the acute treatment of migraine. The TxGNN model predicts it may be effective for migraine with brainstem aura, with a very high prediction score (99.98%), but no clinical trials and no subtype-specific literature currently support this direction — the 19 retrieved publications all concern migraine generally (including menstrual and paediatric migraine), none address the brainstem-aura subtype specifically, and this subtype is one where triptans carry a recognised vasoconstriction safety concern.

Quick Overview

Item	Content
Original Indication	Migraine (acute treatment) — per drug-class positioning in the evidence pack; no ARTG/registration record on file for this jurisdiction
Predicted New Indication	Migraine with brainstem aura
TxGNN Prediction Score	99.98%
Evidence Level	L2
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Naratriptan is a selective 5-HT1B/1D receptor agonist. Its established mechanism treats migraine through intracranial vasoconstriction and inhibition of vasoactive peptide release from the trigeminovascular system — this is its original, non-repurposed core indication.

Migraine with brainstem aura (formerly “basilar-type migraine”) is a subtype of migraine rather than a distinct disease, which is why the TxGNN model scores it so highly against a drug already used for migraine broadly. However, this is exactly where the prediction needs scrutiny rather than acceptance at face value: because this subtype involves brainstem/vertebrobasilar circulation, triptans’ vasoconstrictive mechanism is conventionally flagged as a relative contraindication or warning in major guidance (e.g. AHS assessments, product labelling), out of concern for precipitating brainstem ischaemia. None of the 19 retrieved publications — which cover general acute migraine treatment, menstrual migraine, prodrome prevention, and paediatric use — specifically address efficacy or safety in the brainstem-aura subtype.

In short, the high TxGNN score most likely reflects semantic proximity to “migraine” in the model’s embedding space rather than a genuine, clinically validated new indication. This is a case where the model has not captured a known clinical contraindication signal, and the prediction should be treated as a safety flag for review rather than a repurposing opportunity to pursue.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Note: PubMed’s search matched these publications to “migraine” broadly; none specifically address the migraine-with-brainstem-aura subtype.

PMID	Year	Type	Journal	Key Findings
10972634	2000	RCT	Clinical Therapeutics	Randomised, double-blind, crossover comparison of naratriptan vs. sumatriptan in migraine patients prone to headache recurrence
11264684	2001	RCT	Headache	Double-blind, placebo-controlled trial of naratriptan 1mg/2.5mg twice daily as short-term prophylaxis of menstrually associated migraine
10961768	2000	RCT (prodrome prevention)	Cephalalgia	Investigated naratriptan given during the migraine prodrome to prevent headache onset
25600718	2015	Review/Guideline	Headache	American Headache Society updated evidence assessment of acute migraine pharmacotherapies, including triptans
25841032	2015	Cohort/Comparative	Neurology	Found reduced triptan (sumatriptan) efficacy in migraine with aura vs. without aura — relevant caution for aura subtypes generally
27910087	2017	Review	Headache	Review of treatment options for menstrual migraine
25100506	2014	Review	Expert Opinion on Pharmacotherapy	Updated review of hormonal causes, prophylaxis and treatment of menstrual migraine
16268666	2005	Review	CNS Drugs	Review of triptan use in management of menstrual migraine
22337860	2013	Review	Cephalalgia	Literature review on whether premonitory-phase treatment is a useful migraine management strategy
19126376	2009	Review	Current Pain and Headache Reports	Clinical review of perimenstrual headache classification and treatment

Australia Market Information

No ARTG entries are on file for Naratriptan in this evidence pack — the drug is currently not marketed in this jurisdiction (0 registered licences), so no product/dosage-form table can be produced.

Safety Considerations

Key Mechanistic Safety Signal: Triptans, including naratriptan, act via vasoconstriction. This is mechanistically relevant to migraine with brainstem aura, where vertebrobasilar circulation is involved — a recognised area of caution for this drug class.

Please refer to the TGA-approved Product Information (PI) for full contraindication, warning, and drug-interaction information — no PI-level warnings, contraindications, or drug-drug interaction data were available in this evidence pack (DrugBank DDI query returned no results).

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is a migraine subtype where the drug’s own vasoconstrictive mechanism raises a plausible safety concern rather than a validated efficacy signal, and no clinical trial or subtype-specific literature evidence exists to support it. A blocking data gap on PI-equivalent warnings/contraindications also means the mandatory safety screen (S1) cannot be completed.

To proceed, the following is needed:

TFDA/PI-equivalent label warnings and contraindications (currently blocking — DG001)
Confirmed mechanism-of-action data via DrugBank API (currently missing — DG002)
Drug-drug interaction data (current query returned no results)
Trial or literature evidence specific to the migraine-with-brainstem-aura subtype, particularly addressing vascular safety, before this candidate can move beyond Hold
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.